Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33227
Title: A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: Effects on arterial compliance and endothelial function.
Authors: Zoungas S.;Kotsopoulos D.;Liang Y.-L.;Teede H.J. ;McGrath B.P.;Craven R.
Institution: (Teede, Liang, Kotsopoulos, Zoungas, McGrath) Department of Medicine, Monash University, Dandenong Hospital, Dandenong, Vic., Australia (Craven) Jean Hailes Foundation, 173 Carinish Road, Clayton, Vic., Australia (Teede) Department of Vascular Medicine and Sciences, Dandenong Hospital, David St, Dandenong, Vic. 3175, Australia
Issue Date: 18-Oct-2012
Copyright year: 2001
Publisher: Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)
Place of publication: United Kingdom
Publication information: Clinical Endocrinology. 55 (5) (pp 673-682), 2001. Date of Publication: 2001.
Abstract: OBJECTIVE: To study the effects of long-term combined continuous oral hormone replacement therapy (HRT) on vascular function in healthy postmenopau-sal women. BACKGROUND: The cardiovascular effects of HRT are controversial. Improvement in vascular function is a proposed mechanism of oestrogen action but there are no long-term controlled human trials in this area. In this study, we examined the effects of HRT on lipid profiles and vascular function, encompassing both biomechanical arterial properties [systemic arterial compliance (SAC) and pulse wave velocity (PWV)] and endothelial function [flow-mediated vasodilation (FMD)]. METHOD(S): In this 2-year, double-blind, placebo-controlled study, 59 healthy postmenopausal women were randomized to oral combined continuous oes-trogen and progesterone [Kliogest, oestradiol (2 mg), norethisterone (1 mg)] or placebo, with endpoints measured at baseline, 6 weeks and after 6, 12 and 24 months of treatment. RESULT(S): Oral combined HRT reduced lipoprotein a [Lp(a)], although other lipid benefits were not observed. There were no significant changes in SAC, PWV or FMD with oral combined HRT, compared to placebo. CONCLUSION(S): In this long-term, randomized placebo-controlled trial, oral continuous HRT with combined oestradiol and norethisterone in healthy postmeno-pausal women did not improve a spectrum of indices of arterial function compared to placebo. These results suggest that HRT might not be of cardiovascular benefit in postmenopausal women.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1365-2265.2001.01382.x
PubMed URL: 11894980 [http://www.ncbi.nlm.nih.gov/pubmed/?term=11894980]
ISSN: 0300-0664
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/33227
Type: Article
Type of Clinical Study or Trial: Randomised controlled trial
Appears in Collections:Articles

Show full item record

Page view(s)

18
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.